STAT Plus Sanofi suffered a major setback in its bid to market a controversial dengue vaccine in the U.S. as a FDA advisory committee recommended against approval for adults. httpsbuff.ly2H7lmcHÂ

STAT Plus: Sanofi suffered a major setback in its bid to market a controversial dengue vaccine in the U.S., as a FDA advisory committee recommended against approval for adults. https://buff.ly/2H7lmcH 

STAT Plus: Sanofi suffered a major setback in its bid to market a controversial dengue vaccine in the U.S., as a FDA advisory committee recommended against approval for adults. https://buff.ly/2H7lmcH 

More From BioPortfolio on "STAT Plus: Sanofi suffered a major setback in its bid to market a controversial dengue vaccine in the U.S., as a FDA advisory committee recommended against approval for adults. https://buff.ly/2H7lmcH "